For the 254 million people living with schistosomiasis — a parasitic disease that slowly turns the liver to scar tissue — medicine has long offered only a partial answer. Praziquantel can kill the worms, but it cannot undo the damage they leave behind. Now, researchers in Taiwan have found that naringenin, a compound drawn from the ordinary citrus fruit, may address precisely what the existing drug cannot: the fibrosis, inflammation, and oxidative injury that persist long after the parasite is gone. It is a reminder that some of the most consequential medicines may already exist in nature, wai
PLOS (Public Library of Science)
· Dec 19, 2025
· health
· 15 min read
High
Sourcing: Verified
Citrus compound naringenin shows promise against schistosomiasis-induced liver fibrosis in mice
Schistosomiasis causes approximately 15,000 deaths annually and affects nearly 600 million people at risk in developing countries, with liver fibrosis progression leading to cirrhosis and death.
◉
Health & Medicine
7994 related articles
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 100% match
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% match
Canada faces new COVID epidemic, not third wave, as variants target di…
The Globe and Mail · 99% match
Researchers identify new Ebola variant, propose repurposed drug treatm…
Medical Xpress · 99% match
Dalhousie researchers identify new Ebola variant, propose repurposed d…
Education News Canada · 99% match
Related Coverage
The Guardian · Aug 18
ADHD diagnosis surge raises questions about identity versus disorder
Experts warn that rising ADHD diagnoses increasingly reflect identity-seeking rather than medical need, with poor-qualit…
BBC News · Aug 18 BBC investigation expands: 30 children feared conceived with wrong donors at Cyprus IVF clinicsAt least 30 children, mostly British, are feared conceived via IVF in northern Cyprus using wrong sperm or egg donors th…
News-Medical · Aug 18 IV Iron Use Among Australian Women Surges 17-Fold in DecadeAustralian women's intravenous iron use jumped 17-fold in a decade, with 1 in 20 reproductive-age women receiving treatm…
geneonline.com · Aug 18 1 in 20 Australian Women Now Receiving IV Iron InfusionsOne in 20 Australian women now receive intravenous iron infusions, marking a significant decade-long increase in this tr…
Bias & Framing
⚖
Scientific research article presenting objective findings on a natural compound's therapeutic potential, with minimal bias signals typical of peer-reviewed medical literature.
Bias Direction
center
Confidence
HIGH
Standard scientific reporting using established medical terminology, WHO statistics for context-setting, and mechanistic explanation of disease pathology and treatment mechanism.
Cost-effectiveness analysis or economic accessibility for developing countries most affected
Perspectives from affected communities or patient advocacy groups
Discussion of existing treatment limitations or why current therapies are insufficient
Comparative efficacy data against standard treatments (praziquantel)
Timeline for potential human trials or clinical translation
Geopolitical Impact
🌎
A citrus compound shows therapeutic potential against schistosomiasis-induced liver fibrosis in preclinical research, with implications for treatment in affected developing regions.
Escalation Risk
low
Confidence
MED
Sub-Saharan Africa
Southeast Asia
Middle East
South America
Developing countries globally
This research strengthens the scientific capacity and pharmaceutical development potential of institutions studying tropical diseases, potentially reducing dependency on existing limited treatment options and shifting therapeutic innovation toward natural compound-based solutions.
Similar to historical development of artemisinin from traditional Chinese medicine for malaria treatment, demonstrating how natural compounds can address neglected tropical diseases affecting developing nations.
Economic Lens
📈
Citrus compound naringenin shows therapeutic potential against schistosomiasis-induced liver fibrosis, with implications for pharmaceutical development and tropical disease treatment markets.
Market Signal
neutral
Confidence
LOW
Pharmaceutical and biotechnology
Nutraceuticals and functional foods
Agricultural (citrus production)
Public health and tropical medicine
Medical devices and diagnostics
Potential future treatment option for 254 million infected individuals globally, particularly in developing countries. Could reduce healthcare costs and mortality from schistosomiasis if commercialized. May increase demand for citrus-derived compounds in therapeutic applications.
WHO and national health agencies may prioritize funding for naringenin research and development. Potential regulatory pathways for natural compound drug approval. Could influence public health strategies in endemic regions (sub-Saharan Africa, parts of Asia). May incentivize agricultural investment in citrus cultivation for pharmaceutical purposes.